Xgeva Prostate Cancer Drug Reports Positive Phase III Results

The Phase III study showed the drug increased bone metastasis-free survival for more than four months, delayed the time to first bone metastasis and reduced risk by 15% compared with the placebo.

Amgen's XGEVA (denosumab), a fully human monoclonal antibody which prevents the spread of cancer to the bone in men with advanced prostate cancer, has met primary endpoint from a Phase III trial.

The randomised, placebo-controlled, multicentre Phase III study included 1,432 men with hormone-refractory prostate cancer and showed that the drug increased bone metastasis-free survival for more than four months, delayed the time to first bone metastasis and reduced risk by 15% compared with the placebo.

Massachusetts General Hospital Cancer Center's Boston Genitourinary Malignancies Programme director Matthew Smith said Xgeva is the first and only bone-targeted therapy that has demonstrated the ability to reduce the risk of bone metastasis in men with prostate cancer.